New Preferred Characteristics for Monoclonal Antibodies in Malaria Prevention

By Staff Writer

April 27, 2023

Passive immunization through monoclonal antibodies (mAbs) could potentially provide immediate protection against malaria. To guide the development of urgently needed health products, WHO has published preferred product characteristics (PPCs) for mAbs in malaria prevention. These PPCs aim to reduce morbidity and mortality in infants and children due to Plasmodium falciparum, and highlight the preferred characteristics and clinical development considerations for mAbs in this area. This is an exciting development alongside the development of new malaria vaccines and chemoprevention drugs.

Reference url

Recent Posts

National Health Insurance South Africa
    

Reassuring the Private Sector on National Health Insurance South Africa: A Path to Universal Coverage

🌍 How can South Africa achieve universal healthcare without sidelining private providers?

The National Health Insurance (NHI) represents a pivotal shift in South Africa’s commitment to offering equitable health coverage. Recent assurances from the Treasury highlight a desire to collaborate with the private sector, aiming for a hybrid approach that leverages the best of both worlds.

Curious about how this initiative could reshape the healthcare landscape? Jump into the full article for in-depth insights on the challenges, potential funding models, and the international lessons that can guide this transformative journey.

#SyenzaNews #HealthEconomics #HealthTech #HealthcarePolicy

MASLD CKD socioeconomic link
    

Exploring the MASLD CKD Socioeconomic Link

🌍 Are socioeconomic factors influencing your health more than you realise?

Our latest article looks into the intriguing link between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Chronic Kidney Disease (CKD), revealing significant geographical and socioeconomic correlations. Discover how understanding these relationships can inform public health strategies and improve health equity worldwide.

Dive into the findings and implications for health outcomes!

#SyenzaNews #HealthEconomics #globalhealth #HealthcareInnovation

toripalimab nasopharyngeal carcinoma
        

Toripalimab Evidence Journey in Cancer Care

🚀 How did toripalimab become the first immunotherapy approved in the U.S. for nasopharyngeal carcinoma?

The toripalimab evidence journey began with clinical trials in Asia. The JUPITER-02 trial showed toripalimab plus chemotherapy extended median progression-free survival (PFS) to 21.4 months versus 8.2 months with chemotherapy alone

#SyenzaNews #oncology #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.